วัคซีนโควิด-19
แหล่งข้อมูลอื่น

แม่แบบ:วิกิคำคมอังกฤษ
แม่แบบ:Cite web
แม่แบบ:Cite web
แม่แบบ:วัคซีน
↑  Li, YD; Chi, WY; Su, JH; Ferrall, L; Hung, CF; Wu, TC (December 2020). "Coronavirus vaccine development: from SARS and MERS to COVID-19". Journal of Biomedical Science. 27 (1): 104. doi:10.1186/s12929-020-00695-2. PMC 7749790. PMID 33341119.
↑  Padilla, TB (2021-02-24). "No one is safe unless everyone is safe". BusinessWorld. สืบค้นเมื่อ 2021-02-24.
↑  Vergano, Dan (2021-06-05). "COVID-19 Vaccines Work Way Better Than We Had Ever Expected. Scientists Are Still Figuring Out Why". BuzzFeed News. สืบค้นเมื่อ 2021-06-24.
1 2 3 4 5 6  
"COVID-19 vaccine development pipeline (Refresh URL to update)". Vaccine Centre, London School of Hygiene and Tropical Medicine. 2021-07-12.
↑  
"Approved Vaccines". COVID 19 Vaccine Tracker, McGill University. 2021-07-12.
↑  Beaumont, Peter (2020-11-18). "Covid-19 vaccine: who are countries prioritising for first doses?". The Guardian. ISSN 0261-3077. สืบค้นเมื่อ 2020-12-26.
↑  
Plotkin, Stanley A.; Halsey, Neal (January 2021). "Accelerate COVID-19 Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines". Clinical Infectious Diseases. doi:10.1093/cid/ciab068. PMC 7929065. PMID 33502467.
↑  
Epperly, David (January 2021). "Evidence For COVID-19 Vaccine Deferred Dose 2 Boost Timing". SSRN 3760833.
↑  
Wang, X (February 2021). "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine". N Engl J Med (letter). 384 (11): 1576–78. doi:10.1056/NEJMc2036242. PMID 33596350.
↑  
"More Evidence: Evidence For COVID-19 Vaccine Deferred Dose 2 Boost Timing". ReallyCorrect.com. 2021-05-25.
↑  "Coronavirus (COVID-19) Vaccinations". Our World in Data.
↑  
"Which companies will likely produce the most COVID-19 vaccine in 2021?". Pharmaceutical Processing World (ภาษาอังกฤษแบบอเมริกัน). 2021-02-05. สืบค้นเมื่อ 2021-03-01.
↑  
"China can hit 500-mln-dose annual capacity of CanSinoBIO COVID-19 vaccine this year". ca.sports.yahoo.com (ภาษาอังกฤษแบบแคนาดา). สืบค้นเมื่อ 2021-03-01.{{cite web}}:  CS1 maint: url-status (ลิงก์)
1 2  Mullard, Asher (2020). "How COVID vaccines are being divvied up around the world". Nature. doi:10.1038/d41586-020-03370-6. ISSN 0028-0836.
1 2 3  So, Anthony D; Woo, Joshua (2020-12-15). "Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis". BMJ: m4750. doi:10.1136/bmj.m4750. ISSN 1756-1833.
↑  Coronavirus (COVID-19) Vaccinations. Our World in Data. Sourced from individual health agencies.
↑  Cavanagh, D (December 2003). "Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus". Avian Pathology. 32 (6): 567–82. doi:10.1080/03079450310001621198. PMC 7154303. PMID 14676007.
↑  
Gao, W; Tamin, A; Soloff, A; D'Aiuto, L; Nwanegbo, E; Robbins, PD;  และคณะ (December 2003). "Effects of a SARS-associated coronavirus vaccine in monkeys". Lancet. 362 (9399): 1895–6. doi:10.1016/S0140-6736(03)14962-8. PMC 7112457. PMID 14667748.
↑  
Kim, E; Okada, K; Kenniston, T; Raj, VS; AlHajri, MM; Farag, EA;  และคณะ (October 2014). "Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice". Vaccine. 32 (45): 5975–82. doi:10.1016/j.vaccine.2014.08.058. PMC 7115510. PMID 25192975.
↑  
Greenough, TC; Babcock, GJ; Roberts, A; Hernandez, HJ; Thomas, WD; Coccia, JA;  และคณะ (February 2005). "Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice". The Journal of Infectious Diseases. 191 (4): 507–14. doi:10.1086/427242. PMC 7110081. PMID 15655773.
↑  
Tripp, RA; Haynes, LM; Moore, D; Anderson, B; Tamin, A; Harcourt, BH;  และคณะ (September 2005). "Monoclonal antibodies to SARS-associated coronavirus (SARS-CoV): identification of neutralizing and antibodies reactive to S, N, M and E viral proteins". Journal of Virological Methods. 128 (1–2): 21–8. doi:10.1016/j.jviromet.2005.03.021. PMC 7112802. PMID 15885812.
↑  
Roberts, A; Thomas, WD; Guarner, J; Lamirande, EW; Babcock, GJ; Greenough, TC;  และคณะ (March 2006). "Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters". The Journal of Infectious Diseases. 193 (5): 685–92. doi:10.1086/500143. PMC 7109703. PMID 16453264.
1 2  
Jiang, S; Lu, L; Du, L (January 2013). "Development of SARS vaccines and therapeutics is still needed". Future Virology. 8 (1): 1–2. doi:10.2217/fvl.12.126. PMC 7079997. PMID 32201503.
↑  
"SARS (severe acute respiratory syndrome)". National Health Service. 2020-03-05. เก็บจากแหล่งเดิมเมื่อ 2020-03-09. สืบค้นเมื่อ 2020-01-31.
↑  Shehata, Mahmoud M.; Gomaa, Mokhtar R.; Ali, Mohamed A.; Kayali, Ghazi (2016-01-20). "Middle East respiratory syndrome coronavirus: a comprehensive review". Frontiers of Medicine. 10 (2): 120–136. doi:10.1007/s11684-016-0430-6. PMC 7089261. PMID 26791756.
↑  
Butler, D (October 2012). "SARS veterans tackle coronavirus". Nature. 490 (7418): 20. Bibcode:2012Natur.490...20B. doi:10.1038/490020a. PMID 23038444.
↑  Modjarrad, K; Roberts, CC; Mills, KT; Castellano, AR; Paolino, K; Muthumani, K;  และคณะ (September 2019). "Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial". The Lancet. Infectious Diseases. 19 (9): 1013–1022. doi:10.1016/S1473-3099(19)30266-X. PMC 7185789. PMID 31351922.
↑  Yong, CY; Ong, HK; Yeap, SK; Ho, KL; Tan, WS (2019). "Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus". Frontiers in Microbiology. 10: 1781. doi:10.3389/fmicb.2019.01781. PMC 6688523. PMID 31428074.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  Gates, Bill (2020-04-30). "The vaccine race explained: What you need to know about the COVID-19 vaccine". The Gates Notes. เก็บจากแหล่งเดิมเมื่อ 2020-05-14. สืบค้นเมื่อ 2020-05-02.
↑  "World Health Organization timeline - COVID-19". World Health Organization. 2020-04-27. เก็บจากแหล่งเดิมเมื่อ 2020-04-29. สืบค้นเมื่อ 2020-05-02.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  
Thanh Le, Tung; Andreadakis, Zacharias; Kumar, Arun; Gómez Román, Raúl; Tollefsen, Stig; Saville, Melanie;  และคณะ (2020-04-09). "The COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (5): 305–06. doi:10.1038/d41573-020-00073-5. ISSN 1474-1776. PMID 32273591.
1 2 3 4 5 6 7 8  
Gates, B (February 2020). "Responding to Covid-19: A once-in-a-century pandemic?". The New England Journal of Medicine. 382 (18): 1677–1679. doi:10.1056/nejmp2003762. PMID 32109012.
↑  
Fauci, AS; Lane, HC; Redfield, RR (March 2020). "Covid-19: Navigating the uncharted". The New England Journal of Medicine. 382 (13): 1268–1269. doi:10.1056/nejme2002387. PMC 7121221. PMID 32109011.
↑  Grenfell, Rob; Drew, Trevor (2020-02-17). "Here's Why It's Taking So Long to Develop a Vaccine for the New Coronavirus". ScienceAlert. เก็บจากแหล่งเดิมเมื่อ 2020-02-28. สืบค้นเมื่อ 2020-02-26.
1 2 3 4 5 6 7 8  "Update on WHO Solidarity Trial - Accelerating a safe and effective COVID-19 vaccine". World Health Organization. 2020-04-27. เก็บจากแหล่งเดิมเมื่อ 2020-04-30. สืบค้นเมื่อ 2020-05-02. It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
1 2 3 4 5 6  Yamey, Gavin; Schäferhoff, Marco; Hatchett, Richard; Pate, Muhammad; Zhao, Feng; McDade, Kaci Kennedy (2020-05-02). "Ensuring global access to COVID‑19 vaccines" (PDF). The Lancet. 305: 1405–6. CEPI estimates that developing up to three vaccines in the next 12-18 months will require an investment of at least US$2   billion. This estimate includes phase  1 clinical trials of eight vaccine candidates, progression of up to six candidates through phase  2 and  3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
↑  Schmidt, Charles (2020-06-01). "Genetic Engineering Could Make a COVID-19 Vaccine in Months Rather Than Years". Scientific American. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-08-26.
1 2 3 4 5 6 7 8 9 10 11 12 13 14  Le, Tung Thanh; Cramer, Jakob P.; Chen, Robert; Mayhew, Stephen (2020-09-04). "Evolution of the COVID-19 vaccine development landscape". Nature Reviews Drug Discovery. 19 (10): 667–68. doi:10.1038/d41573-020-00151-8. ISSN 1474-1776. PMID 32887942. S2CID 221503034.
↑  Fox, Chris; Kelion, Leo (2020-07-16). "Russian spies 'target coronavirus vaccine'". BBC News (ภาษาอังกฤษแบบบริติช). เก็บจากแหล่งเดิมเมื่อ 2020-09-04. สืบค้นเมื่อ 2020-08-01.
↑  
"What is the ACT Accelerator?". World Health Organization. 2020. เก็บจากแหล่งเดิมเมื่อ 2020-09-25. สืบค้นเมื่อ 2020-08-29.
↑  
"What is COVAX?". GAVI. 2020-09-01. สืบค้นเมื่อ 2020-12-11.
↑  
"COVAX: CEPI's response to COVID-19". Coalition for Epidemic Preparedness Innovations (CEPI). 2020. สืบค้นเมื่อ 2020-12-15.
1 2  
"New vaccines for a safer world". CEPI. 2020. สืบค้นเมื่อ 2020-12-15.
1 2 3 4  "Our portfolio: partnerships to develop vaccines against COVID-19". CEPI. 2020. สืบค้นเมื่อ 2020-12-15.
↑  "Global equitable access to COVID-19 vaccines estimated to generate economic benefits of at least US$ 153 billion in 2020-21, and US$ 466 billion by 2025, in 10 major economies, according to new report by the Eurasia Group". World Health Organization. 2020-12-04. สืบค้นเมื่อ 2020-12-11.
1 2 3  Wake, Damon (2020-05-04). "EU spearheads $8 billion virus fundraiser". Yahoo Finance. เก็บจากแหล่งเดิมเมื่อ 2020-06-29. สืบค้นเมื่อ 2020-05-04.
1 2  "More than 150 countries engaged in COVID-19 vaccine global access facility". World Health Organization. 2020-07-15. เก็บจากแหล่งเดิมเมื่อ 2020-08-02. สืบค้นเมื่อ 2020-07-25. COVAX is the only truly global solution to the COVID-19 pandemic. For the vast majority of countries, whether they can afford to pay for their own doses or require assistance, it means receiving a guaranteed share of doses and avoiding being pushed to the back of the queue, as we saw during the H1N1 pandemic a decade ago. Even for those countries that are able to secure their own agreements with vaccine manufacturers, this mechanism represents, through its world-leading portfolio of vaccine candidates, a means of reducing the risks associated with individual candidates failing to show efficacy or gain licensure.
↑  "GloPID: Novel coronavirus COVID-19". glopid-r.org. เก็บจากแหล่งเดิมเมื่อ 2020-05-02. สืบค้นเมื่อ 2020-05-02.
1 2  "Government of Canada's research response to COVID-19". Government of Canada. 2020-04-23. เก็บจากแหล่งเดิมเมื่อ 2020-05-13. สืบค้นเมื่อ 2020-05-04.
↑  "ISARIC: COVID-19 clinical research resources". ISARIC. 2020-04-27. เก็บจากแหล่งเดิมเมื่อ 2020-03-30. สืบค้นเมื่อ 2020-05-02.
1 2 3  
"Global Vaccine Summit 2020: World leaders make historic commitments to provide equal access to vaccines for all". Global Alliance for Vaccines and Immunisation. 2020-06-04. เก็บจากแหล่งเดิมเมื่อ 2020-06-06. สืบค้นเมื่อ 2020-06-04.
↑  "Bill & Melinda Gates Foundation pledges US$1.6 billion to Gavi, the Vaccine Alliance, to protect the next generation with lifesaving vaccines". PR Newswire. The Bill & Melinda Gates Foundation. 2020-06-04. เก็บจากแหล่งเดิมเมื่อ 2020-06-04. สืบค้นเมื่อ 2020-06-04.
↑  
Yamada, Haley; Schlosberg, Jon; Tienabeso, Seni (2020-12-10). "Bill and Melinda Gates Foundation announces $250 million COVID vaccine commitment". ABC News - Technology. สืบค้นเมื่อ 2020-12-11.
↑  
"Bill and Melinda Gates call for collaboration, continued innovation to overcome challenges of delivering COVID-19 scientific breakthroughs to the world". Bill & Melinda Gates Foundation. 2020-12-09. สืบค้นเมื่อ 2020-12-11.
1 2 3 4 5 6 7 8 9 10 11 12 13 14  Steenhuysen, Julie; Eisler, Peter; Martell, Allison; Nebehay, Stephanie (2020-04-27). "Special Report: Countries, companies risk billions in race for coronavirus vaccine". Reuters. เก็บจากแหล่งเดิมเมื่อ 2020-05-15. สืบค้นเมื่อ 2020-05-02.
1 2 3 4 5 6 7 8 9 10  
Sanger, David E.; Kirkpatrick, David D.; Zimmer, Carl; Thomas, Katie; Wee, Sui-Lee (2020-05-02). "With Pressure Growing, Global Race for a Vaccine Intensifies". The New York Times. ISSN 0362-4331. เก็บจากแหล่งเดิมเมื่อ 2020-05-11. สืบค้นเมื่อ 2020-05-02.
↑  
Hamilton, Isobel Asher (2020-05-01). "Bill Gates thinks there are 8 to 10 promising coronavirus vaccine candidates and one could be ready in as little as 9 months". Business Insider. เก็บจากแหล่งเดิมเมื่อ 2020-05-16. สืบค้นเมื่อ 2020-05-02.
↑  Jackson, Nick (2020-09-28). "Why we need a "portfolio approach" to COVID-19 vaccine development". CEPI. สืบค้นเมื่อ 2020-12-15.
↑  
"CEPI's COVID-19 vaccine portfolio". CEPI. 2020. สืบค้นเมื่อ 2020-12-15.
↑  
"CEPI and SK bioscience extend collaboration to develop 'next generation' COVID-19 vaccine". CEPI. 2020-12-09. สืบค้นเมื่อ 2020-12-15.
↑  
Abedi, Maham (2020-03-23). "Canada to spend $192M on developing COVID-19 vaccine". Global News. เก็บจากแหล่งเดิมเมื่อ 2020-04-09. สืบค้นเมื่อ 2020-03-24.
↑  
"Government of Canada funds 49 additional COVID-19 research projects - Details of the funded projects". Government of Canada. 2020-03-23. เก็บจากแหล่งเดิมเมื่อ 2020-03-22. สืบค้นเมื่อ 2020-03-23.
↑  Aiello, Rachel (2020-05-04). "'A global challenge': PM Trudeau commits $850 million to global fight against COVID-19". CTV News. เก็บจากแหล่งเดิมเมื่อ 2020-05-10. สืบค้นเมื่อ 2020-05-04.
1 2  Takada, Noriyuki; Satake, Minoru (2020-05-02). "US and China unleash wallets in race for coronavirus vaccine". Nikkei Asian Review. เก็บจากแหล่งเดิมเมื่อ 2020-05-10. สืบค้นเมื่อ 2020-05-03.
↑  Talmazan, Yuliya; Simmons, Keir; Saravia, Laura (2020-05-18). "China's Xi announces $2B for coronavirus response as WHO faces calls for investigation". NBC News. เก็บจากแหล่งเดิมเมื่อ 2020-05-18. สืบค้นเมื่อ 2020-05-18.
↑  Ore, Diego (2020-07-23). "Mexico says China plans $1 billion loan to ease Latam access to virus vaccine". Reuters. เก็บจากแหล่งเดิมเมื่อ 2020-09-25. สืบค้นเมื่อ 2020-08-16.
↑  "China promises Mekong neighbours access to Chinese Covid-19 vaccine". South China Morning Post. 2020-08-24. เก็บจากแหล่งเดิมเมื่อ 2020-09-25. สืบค้นเมื่อ 2020-08-24.
↑  
"CEPI: Our vaccine and platform portfolio". Coalition for Epidemic Preparedness Innovation (CEPI). 2020-04-30. เก็บจากแหล่งเดิมเมื่อ 2020-05-07. สืบค้นเมื่อ 2020-05-03.
↑  
"CEPI collaborates with the Institut Pasteur in a consortium to develop COVID-19 vaccine". Coalition for Epidemic Preparedness Innovations. 2020-03-19. เก็บจากแหล่งเดิมเมื่อ 2020-03-22. สืบค้นเมื่อ 2020-03-23.
↑  "Coronavirus: Commission offers financing to innovative vaccines company CureVac". European Commission. 2020-03-16. เก็บจากแหล่งเดิมเมื่อ 2020-03-19. สืบค้นเมื่อ 2020-03-19.
↑  "Corona-Impfstoff: Bundesregierung beteiligt sich an Impfstoffhersteller CureVac". www.spiegel.de (ภาษาเยอรมัน). Der Spiegel. เก็บจากแหล่งเดิมเมื่อ 2020-06-16. สืบค้นเมื่อ 2020-06-15.
↑  Morriss, Emma (2020-04-22). "Government launches coronavirus vaccine taskforce as human clinical trials start". Pharmafield. เก็บจากแหล่งเดิมเมื่อ 2020-06-17. สืบค้นเมื่อ 2020-05-03.
1 2  
Gartner, Annelies; Roberts, Lizzie (2020-05-03). "How close are we to a coronavirus vaccine? Latest news on UK trials". The Telegraph. ISSN 0307-1235. เก็บจากแหล่งเดิมเมื่อ 2020-05-04. สืบค้นเมื่อ 2020-05-03.
↑  
"Landmark partnership announced for development of COVID-19 vaccine". University of Oxford. 2020-04-30. เก็บจากแหล่งเดิมเมื่อ 2020-05-13. สืบค้นเมื่อ 2020-05-03.
1 2  Kuznia, Robert; Polglase, Katie; Mezzofiore, Gianluca (2020-05-01). "In quest for vaccine, US makes 'big bet' on company with unproven technology". CNN. เก็บจากแหล่งเดิมเมื่อ 2020-05-13. สืบค้นเมื่อ 2020-05-02.
↑  Lee, Carol E; Welker, Kristen; Perlmutter-Gumbiner, Elyse (2020-05-01). "Health officials eyeing at least one of 14 potential coronavirus vaccines to fast-track". NBC News. เก็บจากแหล่งเดิมเมื่อ 2020-05-11. สืบค้นเมื่อ 2020-05-02.
↑  Griffith, Riley; Jacobs, Jennifer (2020-06-03). "White House Works With Seven Drugmakers in 'Warp Speed' Push". Bloomberg. เก็บจากแหล่งเดิมเมื่อ 2020-06-03. สืบค้นเมื่อ 2020-06-04.
↑  "Fact-checking the battle for credit over Pfizer's vaccine announcement". CNN. สืบค้นเมื่อ 2020-11-13. Pfizer is one of various vaccine manufacturers participating in Operation Warp Speed as a supplier of a potential COVID-19 vaccine," Castillo said in an email. "While Pfizer did reach an advanced purchase agreement with the U.S. government, the company did not accept (Biomedical Advanced Research and Development Authority) funding for the research and development process. All the investment for R&D was made by Pfizer at risk. Dr. Jansen was emphasizing that last point.
1 2  "Draft landscape of COVID 19 candidate vaccines". World Health Organization. 2020-12-10. สืบค้นเมื่อ 2020-12-11.
1 2 3 4 5  "An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial" (PDF). World Health Organization. 2020-04-09. เก็บ (PDF)จากแหล่งเดิมเมื่อ 2020-05-12. สืบค้นเมื่อ 2020-05-09.
1 2  
Pallmann, P; Bedding, AW; Choodari-Oskooei, B; Dimairo, M; Flight, L; Hampson, LV;  และคณะ (February 2018). "Adaptive designs in clinical trials: why use them, and how to run and report them". BMC Medicine. 16 (1): 29. doi:10.1186/s12916-018-1017-7. PMC 5830330. PMID 29490655.
↑  
"Adaptive designs for clinical trials of drugs and biologics: Guidance for industry". U.S. Food and Drug Administration (FDA). 2019-11-01. เก็บจากแหล่งเดิมเมื่อ 2019-12-13. สืบค้นเมื่อ 2020-04-03.
↑  McGrail, Samantha (2020-04-15). "Sanofi, GSK partner to develop adjuvanted COVID-19 vaccine". PharmaNewsIntelligence. เก็บจากแหล่งเดิมเมื่อ 2020-05-09. สืบค้นเมื่อ 2020-05-04.
1 2 3 4 5 6 7  
"COVAX: Ensuring global equitable access to COVID-19 vaccines". GAVI. 2020. เก็บจากแหล่งเดิมเมื่อ 2020-09-25. สืบค้นเมื่อ 2020-08-28.
↑  
"R&D Blueprint: A coordinated global research roadmap - 2019 novel coronavirus" (PDF). World Health Organization. 2020-03-01. เก็บ (PDF)จากแหล่งเดิมเมื่อ 2020-05-15. สืบค้นเมื่อ 2020-05-10.
↑  Jeong-ho, Lee; Zheng, William; Zhou, Laura (2020-01-26). "Chinese scientists race to develop vaccine as coronavirus death toll jumps". South China Morning Post. เก็บจากแหล่งเดิมเมื่อ 2020-01-26. สืบค้นเมื่อ 2020-01-28.
↑  Wee, Sui-Lee (2020-05-04). "China's coronavirus vaccine drive empowers a troubled industry". The New York Times. ISSN 0362-4331. เก็บจากแหล่งเดิมเมื่อ 2020-05-04. สืบค้นเมื่อ 2020-05-04.
↑  Simpson, Shmona; Kaufmann, Michael C.; Glozman, Vitaly; Chakrabarti, Ajoy (May 2020). "Disease X: accelerating the development of medical countermeasures for the next pandemic". The Lancet. Infectious Diseases. 20 (5): e108–e115. doi:10.1016/S1473-3099(20)30123-7. ISSN 1474-4457. PMC 7158580. PMID 32197097.
1 2 3 4  "Clinical Development Success Rates 2006-2015" (PDF). BIO Industry Analysis. June 2016. เก็บ (PDF)จากแหล่งเดิมเมื่อ 2019-09-12. สืบค้นเมื่อ 2020-03-23.
↑  
Blackwell, Tom (2020-04-20). "COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work". National Post. สืบค้นเมื่อ 2020-05-03.
↑  
Chen, Justin (2020-05-04). "Covid-19 has shuttered labs. It could put a generation of researchers at risk". STAT. เก็บจากแหล่งเดิมเมื่อ 2020-05-06. สืบค้นเมื่อ 2020-05-04.
1 2 3 4 5 6 7  
Diamond, Michael S; Pierson, Theodore C (2020-05-13). "The challenges of vaccine development against a new virus during a pandemic". Cell Host and Microbe. doi:10.1016/j.chom.2020.04.021. PMC 7219397. PMID 32407708.
1 2  "UK medicines regulator gives approval for first UK COVID-19 vaccine". Medicines and Healthcare Products Regulatory Agency, Government of the UK. 2020-12-02. สืบค้นเมื่อ 2020-12-02.
1 2 3  "Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine". Bahrain News Agency. 2020-12-04. สืบค้นเมื่อ 2020-12-09.
1 2  "UAE: Ministry of Health announces 86 per cent vaccine efficacy". Gulf News. สืบค้นเมื่อ 2020-12-09.
1 2 3  
"Regulatory Decision Summary - Pfizer-BioNTech COVID-19 Vaccine". Health Canada, Government of Canada. 2020-12-09. สืบค้นเมื่อ 2020-12-09.
↑  "Coronavirus: Saudi Arabia approves Pfizer COVID-19 vaccine for use". Al Arabiya English. 2020-12-10. สืบค้นเมื่อ 2020-12-10.
↑  Thomas, Katie (2020-11-20). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". The New York Times. สืบค้นเมื่อ 2020-12-11.
1 2  แม่แบบ:Cite news
↑  "Kuwait authorizes emergency use of Pfizer-BioNTech COVID-19 vaccine". Arab News. 2020-12-13. สืบค้นเมื่อ 2020-12-15.
↑  "Singapore approves use of Pfizer's COVID-19 vaccine". AP NEWS. 2020-12-14. สืบค้นเมื่อ 2020-12-15.
↑  "Jordan approves Pfizer-BioNTech Covid vaccine". France 24. 2020-12-15. สืบค้นเมื่อ 2020-12-15.
↑  "Oman issues licence to import Pfizer BioNTech Covid vaccine - TV". Reuters. 2020-12-15. สืบค้นเมื่อ 2020-12-16.
↑  "Arcsa autoriza ingreso al país de vacuna Pfizer-BioNTech para el Covid-19 - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria" (ภาษาสเปน). สืบค้นเมื่อ 2020-12-17.
↑  "Costa Rica authorizes Pfizer-BioNTech coronavirus vaccine". The Tico Times. 2020-12-16. สืบค้นเมื่อ 2020-12-16.
↑  "Panama approves Pfizer's COVID-19 vaccine - health ministry". Yahoo! Finance. สืบค้นเมื่อ 2020-12-16.
↑  "Chile approves Pfizer-BioNTech Covid-19 vaccine for emergency use". The Straits Times. 2020-12-17. สืบค้นเมื่อ 2020-12-17.
↑  "Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland" (Press release). Swiss Agency for Therapeutic Products (Swissmedic). 2020-12-19. สืบค้นเมื่อ 2020-12-19.
↑  "Qatar approves Pfizer and BioNTech COVID-19 vaccine emergency use". 2020-12-20.
↑  "Questions and Answers: COVID-19 vaccination in the EU". European Commission. 2020-12-21. สืบค้นเมื่อ 2020-12-21.
↑  Campbell, Denis (2020-12-16). "138,000 people in UK receive Covid vaccine in first week". The Guardian.
1 2  Thomas, Katie; LaFraniere, Sharon; Weiland, Noah; Goodnough, Abby; Haberman, Maggie (2020-12-12). "F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away". The New York Times. สืบค้นเมื่อ 2020-12-12.
↑  
"FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine". U.S. Food and Drug Administration (FDA) (Press release). สืบค้นเมื่อ 2020-12-18.
↑  
Oliver, Sara E.; Gargano, Julia W.; Marin, Mona; Wallace, Megan; Curran, Kathryn G.; Chamberland, Mary;  และคณะ (December 2020). "The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine — United States, December 2020" (PDF). MMWR. Morbidity and Mortality Weekly Report. 69 (5152). doi:10.15585/mmwr.mm695152e1.
↑  
Lovelace Jr., Berkeley (2020-12-19). "FDA approves second Covid vaccine for emergency use as it clears Moderna's for U.S. distribution". CNBC. สืบค้นเมื่อ 2020-12-19.
1 2  
"Vaccine Safety - Vaccines". vaccines.gov. US Department of Health and Human Services. เก็บจากแหล่งเดิมเมื่อ 2020-04-22. สืบค้นเมื่อ 2020-04-13.
1 2 3  
"The drug development process". U.S. Food and Drug Administration (FDA). 2018-01-04. เก็บจากแหล่งเดิมเมื่อ 2020-02-22. สืบค้นเมื่อ 2020-04-12.
1 2 3 4 5  Cohen, Jon (2020-06-19). "Pandemic vaccines are about to face the real test". Science. 368 (6497): 1295–6. doi:10.1126/science.368.6497.1295. เก็บจากแหล่งเดิมเมื่อ 2020-06-21. สืบค้นเมื่อ 2020-06-20.
↑  
"How flu vaccine effectiveness and efficacy are measured". Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, US Department of Health and Human Services. 2016-01-29. เก็บจากแหล่งเดิมเมื่อ 2020-05-07. สืบค้นเมื่อ 2020-05-06.
↑  
"Principles of epidemiology, Section 8: Concepts of disease occurrence". Centers for Disease Control and Prevention, Center for Surveillance, Epidemiology, and Laboratory Services, US Department of Health and Human Services. 2012-05-18. เก็บจากแหล่งเดิมเมื่อ 2020-04-06. สืบค้นเมื่อ 2020-05-06.
↑  "Vaxzevria (previously COVID-19 Vaccine AstraZeneca) EPAR". European Medicines Agency (EMA).
↑  "AstraZeneca & Serum Institute of India sign licensing deal for 1 million doses of Oxford vaccine". The Economic Times. สืบค้นเมื่อ 2020-06-15.
↑  "Covid-19 vaccine: Serum Institute signs up for 100 million doses of vaccines for India, low and middle-income countries". The Financial Express. 2020-08-07.
↑  Walsh, Nick; Shelley, Jo; Duwe, Eduardo; Bonnett, William (2020-07-27). "The world's hopes for a coronavirus vaccine may run in these health care workers' veins". CNN. São Paulo. สืบค้นเมื่อ 2020-08-03.
1 2  
"Investigating a Vaccine Against COVID-19". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-05-26. NCT04400838. เก็บจากแหล่งเดิมเมื่อ 2020-10-11. สืบค้นเมื่อ 2020-07-14.
↑  
"A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19". EU Clinical Trials Register (Registry). European Union. 2020-04-21. EudraCT 2020-001228-32. เก็บจากแหล่งเดิมเมื่อ 2020-10-05. สืบค้นเมื่อ 2020-08-03.
↑  
O'Reilly, Peter (2020-05-26). "A Phase III study to investigate a vaccine against COVID-19". ISRCTN (Registry). doi:10.1186/ISRCTN89951424. ISRCTN89951424.
↑  Gallagher, James; Triggle, Nick (2020-12-30). "Covid-19: Oxford-AstraZeneca vaccine approved for use in UK". BBC News Online. สืบค้นเมื่อ 2020-03-05.
↑  AstraZeneca COVID-19 Vaccine (PDF) (Product Monograph). AstraZeneca. 2021-02-26. 244627. คลังข้อมูลเก่าเก็บจากแหล่งเดิม (PDF)เมื่อ 2021-03-30. สืบค้นเมื่อ 2021-03-05.
↑  "A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19". ClinicalTrials.gov (Registry). United States National Library of Medicine. 2020-05-12. NCT04383574. เก็บจากแหล่งเดิมเมื่อ 2020-08-23. สืบค้นเมื่อ 2020-08-26.
1 2  Voysey, M; SA, Costa Clemens; Madhi, SA; Weckx, LY; Folegatti, PM; Aley, PK;  และคณะ (March 2021). "Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials". Lancet. 397 (10277): 881–91. doi:10.1016/S0140-6736(21)00432-3. PMC 7894131. PMID 33617777.
↑  "Trial of Oxford COVID-19 vaccine starts in Brazil". Jenner Institute. เก็บจากแหล่งเดิมเมื่อ 2020-09-09. สืบค้นเมื่อ 2020-08-26.
↑  "Oxford COVID-19 vaccine final trials will be held in these 17 hospitals in India". mint. 2020-08-19.
1 2 3  Md, Jens D. Lundgren (2021-02-18). "National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)". ClinicalTrials.gov. สืบค้นเมื่อ 2021-06-01.